Table 3 Association between IL-6 and IL-8 after ICI therapy and clinical outcome
Biomarker | NSCLC stage (n) | Treatment | Direction after treatment | Association with clinical outcome | Ref | |||
|---|---|---|---|---|---|---|---|---|
Response | PFS | OS | ||||||
Cytokine | IL-6 | III-IV (n = 103) | αPD-1, αPD-L1, αPD-1/chemo, αPD-L1/chemo | ↑ | ↓ (p < 0.001) | [25] | ||
Metastatic (n = 47) | αPD-1, αPD-L1 | ↑ | ↓ (p = 0.01) | ↓ (p = 0.03) | [39] | |||
IIIB-IV (n = 143) | αPD-1, αPD-L1, αPD-1/chemo | ↑ | ↓ (p < 0.001) | [31] | ||||
IL-8 | Metastatic (n = 19) | αPD-1 | ↑ | ↓ (p < 0.0001) | ↓ (p = 0.004) | [40] | ||
II-IV (n = 27) | αPD-1 | ↑ | ns | ↓ (p = 0.025) | [41] | |||
III-IV (n = 44) | αPD-1/radiotherapy | ↑ | ↓ (p < 0.05) | ↓ (p = 0.0058) | [42] | |||
IIIB-IV (n = 143) | αPD-1, αPD-L1, αPD-1/chemo | ↑ | ↓ (p < 0.05) | ↓ (p = 0.0146) | [31] | |||
↑ IL-8 and CXCL10 (model) | ↓ (p = 0.087) | |||||||
II-IV lung cancer (n = 67, with NSCLC, n = 57) | αPD-1/chemo | ↑ CXCL10:IL-8 | ↑ (p = 0.0005) | ↑ (p = 0.0006) | [43] | |||